These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

448 related items for PubMed ID: 19245518

  • 1. The role of the renin-angiotensin system in the pathophysiology, prevention, and treatment of renal impairment in patients with the cardiometabolic syndrome or its components.
    Alpert MA, Govindarajan G, Del Rosario ML, Reisin E.
    J Cardiometab Syndr; 2009; 4(1):57-62. PubMed ID: 19245518
    [Abstract] [Full Text] [Related]

  • 2. Renin-angiotensin-aldosterone system intervention in the cardiometabolic syndrome and cardio-renal protection.
    Whaley-Connell A, Pavey BS, Chaudhary K, Saab G, Sowers JR.
    Ther Adv Cardiovasc Dis; 2007 Oct; 1(1):27-35. PubMed ID: 19124393
    [Abstract] [Full Text] [Related]

  • 3. Obesity, cardiometabolic syndrome, and chronic kidney disease: the weight of the evidence.
    Lastra G, Manrique C, Sowers JR.
    Adv Chronic Kidney Dis; 2006 Oct; 13(4):365-73. PubMed ID: 17045222
    [Abstract] [Full Text] [Related]

  • 4. Mechanisms of hypertension in the cardiometabolic syndrome.
    Redon J, Cifkova R, Laurent S, Nilsson P, Narkiewicz K, Erdine S, Mancia G.
    J Hypertens; 2009 Mar; 27(3):441-51. PubMed ID: 19262221
    [Abstract] [Full Text] [Related]

  • 5. Renin-angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: an integrated view in humans.
    Sarzani R, Salvi F, Dessì-Fulgheri P, Rappelli A.
    J Hypertens; 2008 May; 26(5):831-43. PubMed ID: 18398321
    [Abstract] [Full Text] [Related]

  • 6. The role of obesity and its bioclinical correlates in the progression of chronic kidney disease.
    Chalmers L, Kaskel FJ, Bamgbola O.
    Adv Chronic Kidney Dis; 2006 Oct; 13(4):352-64. PubMed ID: 17045221
    [Abstract] [Full Text] [Related]

  • 7. Supratherapeutic doses of angiotensin receptor blockers to decrease proteinuria in patients with chronic kidney disease.
    Palmer BF.
    Am J Nephrol; 2008 Oct; 28(3):381-90. PubMed ID: 18063856
    [Abstract] [Full Text] [Related]

  • 8. Insulin resistance and endothelin: another pathway for renal injury in patients with the cardiometabolic syndrome?
    Sarafidis PA, Lasaridis AN.
    J Cardiometab Syndr; 2008 Oct; 3(3):183-7. PubMed ID: 18983337
    [Abstract] [Full Text] [Related]

  • 9. [Inhibition of the renin-angiotensin system to prevent target organ damage: the "renal continuum"].
    Tislér A.
    Orv Hetil; 2003 May 04; 144(18 Suppl 1):898-901. PubMed ID: 12785234
    [Abstract] [Full Text] [Related]

  • 10. Molecular mechanisms for vascular injury in the metabolic syndrome.
    Yamagishi S, Nakamura K, Jinnouchi Y, Takenaka K, Imaizumi T.
    Drugs Exp Clin Res; 2005 May 04; 31(3):123-9. PubMed ID: 16033251
    [Abstract] [Full Text] [Related]

  • 11. Metabolic syndrome and cardiovascular risk in primary hypertension.
    Ratto E, Leoncini G, Viazzi F, Vaccaro V, Parodi A, Falqui V, Conti N, Tomolillo C, Deferrari G, Pontremoli R.
    J Am Soc Nephrol; 2006 Apr 04; 17(4 Suppl 2):S120-2. PubMed ID: 16565234
    [Abstract] [Full Text] [Related]

  • 12. Renin-angiotensin system inhibitors in proteinuric chronic kidney disease.
    Hirsch S.
    Compr Ther; 2009 Apr 04; 35(2):91-5. PubMed ID: 19618757
    [Abstract] [Full Text] [Related]

  • 13. The renoprotective effects of RAS inhibition: focus on prevention and treatment of chronic kidney disease.
    Weir MR.
    Postgrad Med; 2009 Jan 04; 121(1):96-103. PubMed ID: 19179817
    [Abstract] [Full Text] [Related]

  • 14. Sex and the renin angiotensin system: implications for gender differences in the progression of kidney disease.
    Sandberg K, Ji H.
    Adv Ren Replace Ther; 2003 Jan 04; 10(1):15-23. PubMed ID: 12616459
    [Abstract] [Full Text] [Related]

  • 15. Prerenal success in chronic kidney disease.
    Hirsch S.
    Am J Med; 2007 Sep 04; 120(9):754-9. PubMed ID: 17765040
    [Abstract] [Full Text] [Related]

  • 16. Urinary angiotensinogen as a marker of intrarenal angiotensin II activity associated with deterioration of renal function in patients with chronic kidney disease.
    Yamamoto T, Nakagawa T, Suzuki H, Ohashi N, Fukasawa H, Fujigaki Y, Kato A, Nakamura Y, Suzuki F, Hishida A.
    J Am Soc Nephrol; 2007 May 04; 18(5):1558-65. PubMed ID: 17409316
    [Abstract] [Full Text] [Related]

  • 17. [Chronic renal insufficiency and cardiovascular disease].
    Charriere S, Rognant N, Chiche F, Cremer A, Deray G, Priou M.
    Ann Cardiol Angeiol (Paris); 2009 Feb 04; 58(1):40-52. PubMed ID: 18937921
    [Abstract] [Full Text] [Related]

  • 18. Renal manifestations in the metabolic syndrome.
    Locatelli F, Pozzoni P, Del Vecchio L.
    J Am Soc Nephrol; 2006 Apr 04; 17(4 Suppl 2):S81-5. PubMed ID: 16565254
    [Abstract] [Full Text] [Related]

  • 19. Link between the renin-angiotensin system and insulin resistance: implications for cardiovascular disease.
    Zhou MS, Schulman IH, Zeng Q.
    Vasc Med; 2012 Oct 04; 17(5):330-41. PubMed ID: 22814999
    [Abstract] [Full Text] [Related]

  • 20. Pancreatic renin-angiotensin-aldosterone system in the cardiometabolic syndrome and type 2 diabetes mellitus.
    Hayden MR, Sowers JR.
    J Cardiometab Syndr; 2008 Oct 04; 3(3):129-31. PubMed ID: 18983326
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.